Focused On-demand Library for Glycine receptor subunit alpha-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P23416

UPID:

GLRA2_HUMAN

Alternative names:

Alternative UPACC:

P23416; A8K0J6; B2R6I8; B7Z4F5; J3KQ59; Q53YX7; Q6ICQ0; Q99862

Background:

The Glycine receptor subunit alpha-2 plays a pivotal role in the central nervous system as a ligand-gated chloride channel. Its activation by glycine, taurine, and beta-alanine facilitates the generation of inhibitory postsynaptic currents, crucial for maintaining the balance of neuronal excitability. This receptor's involvement in synaptic plasticity and cellular responses to ethanol underscores its significance in neurophysiological processes.

Therapeutic significance:

Intellectual developmental disorder, X-linked, syndromic, Pilorge type, a condition marked by developmental delays, speech impediments, and behavioral issues, is directly linked to mutations affecting the Glycine receptor subunit alpha-2 gene. This association highlights the receptor's therapeutic potential in addressing neurodevelopmental disorders.